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Probably the most important change in der-matological care over the next quarter century will be the introduction of strati-
fied medicine into routine clinical practice (Bell, 
2014). This is a common goal of physicians, 
industry, and patients. Stratified medicine is not 
a new concept and is synonymous with the term 
personalized or precision medicine. It is best 
understood as a process that moves prescribing 
from its current “trial-and-error” basis to one that 
is targeted not only to the causes of disease but 
also to the needs of the individual patient, there-
by fulfilling the premise of the right drug for the 
right patient. The ability to prosecute a stratified 
approach to prescribing has been led by the field 
of oncology in which most new therapies are 
released alongside a companion diagnostic. For 
instance, in the targeted management of breast 
cancer, trastuzumab is preferentially prescribed to 
those patients whose cancer expresses the human 
EGF receptor-2 (Slamon and Pegram, 2001).
The stratified medicine approach is begin-
ning to percolate into the management of 
immune-mediated inflammatory disease. For 
instance, the anti-IL-13 biologic lebrikizumab 
is known to be far more effective for the treat-
ment of asthma patients with high, as opposed 
to low, serum levels of periostin (Corren et al., 
2011). In the management of inflammatory 
skin disease, the stratified approach is nascent 
but its successful prosecution will require 
close partnership among clinicians, scientists, 
patients, and industry. The development of the 
UK Medical Research Council (MRC)–funded 
stratified medicine consortium in psoriasis—
Psoriasis Stratification to Optimize Relevant 
Therapy (PSORT)—is an excellent example of 
such partnership working, which is so vital to 
the concept of translational research whereby 
discovery and proof-of-principle testing can 
lead to improved patient care and commer-
cialization. In December 2011, the British 
prime minister, David Cameron, announced a 
research initiative on stratification of disease to 
be implemented by the MRC. An application 
was made to this call for psoriasis to be rec-
ognized as an exemplar disease for stratifica-
tion with an initial focus on biologic therapies. 
This Editorial provides the background and 
objectives to the PSORT consortium that com-
menced in September 2014.
The genesis of the consortium goes back 30 
years, to the early 1980s, when the initial chal-
lenges to the dogma of psoriasis as primarily a 
disorder of epidermal keratinocytes were made 
and the concept of the central pathomechanis-
tic role of T cells was introduced (Valdimarsson 
et al., 1986). This new paradigm was cemented 
by the observation that cyclosporine (a rudi-
mentary T-cell-targeted approach) was an effec-
tive therapy for psoriasis—a consequence of an 
academic–industry collaboration with Sandoz, 
then the manufacturers of the drug (Griffiths 
et al., 1986). Further evidence of academic–
industry collaboration arose from a number of 
sources, including Gottlieb, who reported that 
a lymphocyte-selective toxin, DAB389 IL-2, tar-
geted to IL-2R-expressing cells (i.e., T cells as 
opposed to keratinocytes) was an effective ther-
apy for psoriasis (Gottlieb et al., 1995). The bio-
logic era for psoriasis dawned with the approval 
of alefacept (Ellis and Krueger, 2001), followed 
by efalizumab and cytokine-targeted therapies, 
primarily tumor necrosis factor (TNF)-α and 
then IL-12/IL-23 (ustekinumab). The approval of 
the first of the anti-IL-7 biologics, secukinum-
ab, for the treatment of moderate to severe pso-
riasis in the United States and European Union 
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occurred in early 2015 (Sanford and McKeage, 2015). A 
notable feature of this journey has been the close working 
relationship between clinicians, scientists, and industry—a 
necessary tripartite partnership in translational research.
Although biologic therapies have been transformational 
in the management of severe psoriasis, the known variabil-
ity in both the short-term response and the persistence of that 
response to the drug is problematic. Such problems are trac-
table by a stratified approach. Psoriasis is a model disease for 
stratification because (i) unlike in other immune-mediated 
inflammatory diseases, such as rheumatoid arthritis, biologics 
are licensed for use as monotherapy; (ii) response to therapy 
is relatively easy to quantify and; (iii) the diseased tissue (skin) 
is accessible for sequential sampling by biopsy—a minimally 
invasive and patient-accepted technique. The MRC’s guid-
ance specified that the consortium should embrace open col-
laboration rather than competition, with sharing of expertise 
across institutes and sectors with industry engaged as equal 
partners from the outset. The consortium is to be a dynamic 
platform and the programmatic support is milestone-driven. 
In October 2012, key UK academics and clinicians with 
expertise in treating psoriasis and potential industry part-
ners united by a strong research interest in the disease came 
together in a one-day scoping workshop in London, funded 
by the MRC and chaired by Sir John Bell. This invaluable 
meeting enabled active engagement among potential inves-
tigators, industry, and the Psoriasis Association of Great 
Britain and Ireland. Industry partners embraced the oppor-
tunities inherent in the stratified medicine approach to 
managing psoriasis and were generous in offers of support 
ranging from in-house expertise to data sets to finance. This 
formed the basis for the PSORT consortium application to 
the MRC in 2013. Using biologic therapies as the target for 
stratification, the main objective of PSORT is to use clini-
cal, pharmacological, genetic, and immune biomarkers to 
predict and reproducibly stratify the response of psoriasis to 
biologic therapies. This could result in biologics being used 
at minimal effective doses and form the basis for an algo-
rithm or stratifier scalable for clinical use with the potential 
for significant health-care savings. 
The success of the PSORT application is founded on four 
pillars: (i) the main academic applicants have collaborated 
successfully for many years (in some cases, more than 20) 
on different aspects of psoriasis research and clinical man-
agement (Smith et al., 2009; Strange et al., 2010); (ii) the 
bioresource available to the consortium in the form of the 
British Association of Dermatologists Biologic Interventions 
Register (http://www.badbir.org (see Box 1); Burden et al., 
2012) to test the clinical utility of biomarkers; (iii) the track 
record of the investigators’ collaboration with industry for 
many years; (iv) the involvement of expertise beyond basic 
science and dermatology, including bioinformatics, systems 
medicine, biostatistics, health economics, pharmacology, 
and research management; and (v) the involvement from 
the outset of patients in the planning and design of the stud-
ies that form the Work Strands of the consortium. 
The work of PSORT is structured around a dynamic 
integrative platform of two related elements of research, 
or Work Strands: (i) Clinical and Pharmacology Studies; 
and (ii) Immune Biomarkers in Skin and Blood. The Work 
Strands move the research questions through the traditional 
discovery, refinement, and validation phases (Figure 1). An 
objective of the PSORT program is to identify and charac-
terize psoriasis endotypes (endophenotypes). This termi-
nology was first introduced into the asthma field to define 
subtypes of disease, both functionally and pathologically, 
by a molecular mechanism or by a treatment response 
(Anderson, 2008). 
PSORT’s work will focus on adalimumab (anti-TNF), 
ustekinumab (anti-IL-12/23), and secukinumab (anti-IL-
17A) in the first instance, but the dynamic aspect of the 
program allows inclusion of new biologics and small mol-
ecules as they become available for psoriasis. Work Strand 
1 involves discovering disease endotypes associated with 
treatment outcome; assessing the influence of blood drug 
levels and antidrug antibodies on outcome; and assessment 
of adherence. Work Strand 2 concerns the discovery and 
Box 1. The British Association Of 
Dermatologists Biologic Interventions 
Register (BADBIR)
• Founded in 2007; funded until at least 2017
• Unique, long-term, Web-based pharmacovigilance 
register for psoriasis patients on biologic or 
conventional systemic therapies
• Viewed as international gold standard psoriasis 
registry
• 152 Dermatology Centres in the United Kingdom 
and Ireland recruiting to BADBIR
• 11,048 patients recruited: 7,102 on biologics and 
3,946 on conventional systemic therapies
• High-quality phenotypic and quantitative disease 
severity data
• High-quality follow-up data on response to therapy 
and persistence of response
• More than 30% have serial serum samples and/or 
RNA and DNA banked
Source: http://www.badbir.org
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validation of molecular and immune signatures (comprising 
disease and drug endotypes), in skin and blood, that stratify 
responses and assessment of key biomarkers for investiga-
tion of mechanisms of response. 
The results of these investigations are stored in a 
tranSMART data warehouse (http://www.transmartfounda-
tion.org), allowing seamless integration of PSORT multi-
omic data and clinical phenotypes with a highly curated 
selection of preexisting public data. TranSMART offers the 
PSORT consortium and partners a unified, secure, and 
importantly sustainable research environment to apply a 
range of systems biological and machine learning methods 
for biomarker discovery. As the PSORT project scales in 
its data generation and integration, hosting of the PSORT–
tranSMART will be transferred to the MRC-eMEDLAB, 
providing direct, secure access to substantial high-perfor-
mance computing facilities. There is both the ability and the 
desire to add data from other resources (e.g., the European 
Molecular Biology Laboratory and ENCODE) as and when 
they become available, which will, in turn, help to ensure 
the durability of the consortium. 
The consortium is composed of 18 partners, all of whom 
have signed a legally binding consortium agreement, a liv-
ing document that determines, among other operational 
issues, the detail of intellectual property (both background 
and foreground) and commercialization of discoveries. 
There are currently 10 industry partners (7 pharmaceu-
tical and 3 diagnostic companies; Table 1), but it is likely 
that this will change over the 4 years of the consortium 
as partners may, under the terms of the agreement, either 
leave or join PSORT. Examples of industry engagement in 
PSORT ranges from in-house expertise on development of 
the tranSMART data warehouse (Janssen), RNA Seq analy-
sis (GSK-Stiefel), and embedding of PSORT Work Strand 2 
objectives of sequential sampling for skin and blood tran-
scriptomics in a subset of subjects in a UK commercial 
phase III trial of secukinumab in psoriasis patients deemed 
to have failed TNF-inhibitor biologics (Novartis). The diag-
nostic companies will engage more fully if and when a 
scalable stratifier for predicting response to biologics or a 
biologic is identified. Perhaps the crux of the MRC and the 
UK government’s strategic investment in this area is that 
industry wishes to be involved in PSORT and stratification 
of psoriasis is important to them. Such interest can be artic-
ulated thus: (i) taxonomic classification of psoriasis, based 
on mechanisms, will identify cohorts of patients suited to 
proof-of-principle testing of new molecules; (ii) stratifica-
tion tools will facilitate accurate targeting of new molecules 
to patient/drug endotype; (iii) establishment of minimal 
effective dosing will inform best practice; (iv) PSORT will 
inform other IMIDs because psoriasis is the lead disease for 
new molecules (e.g., anti-IL-17 and anti-IL-12/23); and (v) 
value will be added through cross-referencing of data in 
other MRC-funded stratified medicine programs (e.g., rheu-
matoid arthritis–MATURA consortium) using tranSMART. 
The PSORT consortium’s collaborators include those 
who curate databases, psoriasis patient cohorts, and regis-
tries in Europe and the United States. The management of 
the consortium places partnership with industry at its heart 
in that the steering committee is cochaired by the director 
Figure 1. Psoriasis Stratification to Optimize Relevant Therapy (PSORT) stratification plan. The dynamic platform consists of two integrated Work Strands 
(WS): Clinical and Pharmacology Studies and Immune Biomarkers in Skin and Blood. Three biologics—adalimumab (TNFi), secukinumab (IL17i), and 
ustekinumab (IL12/23i)—will be assessed via serial serum samples for drug levels, antidrug antibodies, and serial sampling of skin and blood for mRNA and 
immune biomarkers in an initial discovery phase. Refinement of identified signatures will be validated in the British Association of Dermatologists Biologic 
Interventions Register bioresource. Data are collected via a TranSMART data warehouse. The PSORT stratifier for psoriasis and drug response endotypes will be 
subject to clinical trial in the UK National Health Service to assess utility and feasibility and potential for health-care savings.
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(clinical academic) and the chair of the industry partner 
subgroup; both Work Strands have industry coleads and a 
separate intellectual property and commercialization sub-
group is represented on the steering committee by its chair, 
as is the patients subgroup. The durability and future-proof-
ing of the consortium beyond its initial 4 years of funding 
are dependent on additional industry and academic part-
ners. For further information, please refer to the consor-
tium’s website, http://www.psort.org.uk.
One may ask what the drive is for industry to collabo-
rate so readily with PSORT. Industry participation in PSORT 
is driven strongly by the opportunity to be able to select 
the right patients to test new therapies definitively based 
on large, well-phenotyped patient cohorts and associated 
molecular tests. Ultimately, this will reduce the cost of devel-
opment by eliminating failures early and accelerate clinical 
development of the best new entities. Industry also appreci-
ates that obtaining regulatory and cost/benefit approval for 
expensive, potent biologic therapies in dermatology does, 
and will, require it to acquire a considerable body of positive 
evidence of efficacy, safety, health, economic, and patient 
outcome data. PSORT promises to create the leading “public 
sector/clinically led” stratified medicine development plat-
form that will provide the optimal environment for it to cre-
ate this body of data as efficiently as possible.
Stratified medicine is the great ambition of clinical trans-
lational research and will, in our opinion, change the land-
scape of dermatological practice in the next decade. To real-
ize this requires big team science working in open collabo-
ration with the commercial sector and with patient groups. 
That the MRC has selected psoriasis as 1 of only 12 diseases 
across the whole of medicine worthy of programmatic invest-
ment is a unique and exciting opportunity for those of us 
involved in psoriasis research and treatment. If successful, 
PSORT will benefit patients, health-care practitioners, and 
industry and will act as a platform for innovation, commer-
cialization, and international research collaboration.
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